COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen A/S announced today that it has been granted European Patent number 1,283,720 B1 for use of polyclonal antibodies for allergy indications. The patent broadly covers the manufacture and use of allergen-specific polyclonal antibodies for the prevention and treatment of allergic reactions. Symphogen holds equivalent patents in the United States and India and has pending patents in additional countries.
